Skip to main content

Fennec Pharmaceuticals Inc (FRX-T) Quote

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 5.01
Day High 5.27
Open:5.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results
GlobeNewswire - Thu May 9, 5:02AM CDT
GlobeNewswire - CMTX
Thu May 9, 5:02AM CDT
-- Strong financial position with $20.2 million in cash and no debt
Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results
GlobeNewswire - Wed Mar 13, 5:19AM CDT
GlobeNewswire - CMTX
Wed Mar 13, 5:19AM CDT
-- Initiated rolling New Drug Application to U.S. FDA for PEDMARK
Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
GlobeNewswire - Mon Feb 4, 4:59AM CST
GlobeNewswire - CMTX
Mon Feb 4, 4:59AM CST
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate (STS) to be administered by infusion) for the prevention of ototoxicity induced by cisplatin chemotherapy in pediatric patients with solid tumors, announced a $12.5 million senior debt facility with the Life Sciences Group at Bridge Bank.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 4.72 +6.14% increase
on 06/28/19
Period Open:5.15
Price movement based on the high, low and last over the given period.
5.83 -14.07% decrease
on 06/18/19
-0.14 (-2.72%) decrease
since 06/17/19
3-Month 4.35 +15.17% increase
on 06/12/19
Period Open:6.32
Price movement based on the high, low and last over the given period.
6.48 -22.69% decrease
on 04/22/19
-1.31 (-20.73%) decrease
since 04/17/19
52-Week 4.35 +15.17% increase
on 06/12/19
Period Open:12.39
Price movement based on the high, low and last over the given period.
13.79 -63.67% decrease
on 08/13/18
-7.38 (-59.56%) decrease
since 07/17/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).